Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Chest

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/chest.124.4_meetingabstracts.254sPMID 14665529
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

  2003cited by this paper
• Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

  2003cited by this paper
• Effects of Tumor Necrosis Factor Alpha on Dendritic Cell Accumulation in Lymph Nodes Draining the Immunization Site and the Impact on the Anticryptococcal Cell-Mediated Immune Response

  2003cited by this paper
• Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab.

  2002cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Role of TNF-alpha in the induction of fungicidal activity of mouse peritoneal exudate cells against Cryptococcus neoformans by IL-12 and IL-18.

  1999cited by this paper
• Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans.

  1996cited by this paper
• The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors.

  1981cited by this paper

• TNF Inhibitor‐Induced Sarcoidosis‐Like Lesions in Inflammatory Bowel Disease

  2025cites this paper
• Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis

  2025cites this paper
• Pulmonary Cryptococcosis With Rapid Growth on Positron Emission Tomography/Computed Tomography

  2025cites this paper
• Infections in the era of immunobiologicals

  2024cites this paper
• Cryptococcosis Associated With Biologic Therapy: A Narrative Review

  2024cites this paper
• Cryptococcosis and Cryptococcal Meningitis: A Narrative Review and the Up-to-Date Management Approach

  2024cites this paper
• Characteristics of pulmonary cryptococcosis in patients with rheumatoid arthritis

  2021cites this paper
• Fungal Infections Potentiated by Biologics.

  2020cites this paper
• Cryptococcal Immune Reconstitution Inflammatory Syndrome: a Paradoxical Response to a Complex Organism

  2020cites this paper
• Possible environmental exposure-associated pulmonary cryptococcosis in a patient with rheumatoid arthritis: a case report and literature review

  2020cites this paper
• Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies.

  2019cites this paper
• Epigenetic stabilization of DC and DC precursor classical activation by TNFα contributes to protective T cell polarization

  2019cites this paper
• Cryptococcal Meningitis: A Deadly Fungal Disease of Peoples Living with HIV/AIDS: Improving Access to Essential Antifungal Medicines: A Review Study

  2018cites this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).

  2018cites this paper
• Lung Disease Associated with Rheumatoid Arthritis

  2018cites this paper
• Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis.

  2017cites this paper
• Mycophenolate mofetil increases susceptibility to opportunistic fungal infection independent of lymphocytes

  2017cites this paper
• CRYPTOCOCCOSIS AMONG HIV PATIENTS

  2017cites this paper
• Pulmonary Cryptococcosis Developed from a Nodule after Treatment with Infliximab for Arthritis Associated with Ulcerative Colitis.

  2017cites this paper
• The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum

  2016cites this paper
• Cryptococcal Disease in HIV-Infected Children

  2016cites this paper
• Review of pulmonary adverse effects of infliximab therapy in Crohn’s disease

  2016cites this paper
• Breakthrough disseminated cryptococcosis during micafungin therapy.

  2015cites this paper
• Mononuclear phagocyte-mediated antifungal immunity: the role of chemotactic receptors and ligands

  2015cites this paper
• Role of dendritic cell-pathogen interactions in the immune response to pulmonary cryptococcal infection.

  2015cites this paper
• Abdominal Lymphonodular Cryptococcosis in an Immunocompetent Child

  2015cites this paper
• Cryptococcal meningitis: epidemiology and therapeutic options

  2014cites this paper
• Risk of infections with biological agents.

  2014cites this paper
• Cryptococcus neoformans meningoencephalitis in a patient with polyarteritis nodosa

  2014cites this paper
• Cryptococcal meningitis: epidemiology and therapeutic options

  2014cites this paper
• Cryptococcal meningitis: epidemiology and therapeutic options

  2014cites this paper
• Disseminated cryptococcosis in a diabetic patient.

  2014cites this paper
• Cryptococcal Meningitis in Patients with Autoimmune Hemolytic Anemia

  2014cites this paper
• Pulmonary Cryptococcosis That Mimicked Rheumatoid Nodule in Rheumatoid Arthritis Lesion

  2014cites this paper
• The deubiquitinase A20 in immunopathology of autoimmune diseases

  2014cites this paper
• Predictors of Mortality and Differences in Clinical Features among Patients with Cryptococcosis According to Immune Status

  2013cites this paper
• Pulmonary cryptococcosis in rheumatoid arthritis (RA) patients: comparison of imaging characteristics among RA, acquired immunodeficiency syndrome, and immunocompetent patients.

  2013cites this paper
• [Immune reconstitution inflammatory syndrome in cryptococcal meningitis: a rare phenomenon?].

  2012cites this paper
• Possible pulmonary cryptococcosis in a patient with Crohn's disease during anti-tumor necrosis factor-alpha treatment: a case report and literature review.

  2012cites this paper
• An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

  2011cites this paper
• Methylxanthine Inhibit Fungal Chitinases and Exhibit Antifungal Activity

  2011cites this paper
• Chemokine receptor 2-mediated accumulation of fungicidal exudate macrophages in mice that clear cryptococcal lung infection.

  2011cites this paper
• Host Defenses Against Cryptococcosis

  2011cites this paper
• Pulmonary Cryptococcosis

  2011cites this paper
• Asymptomatic pulmonary cryptococcosis in a patient with Crohn's disease on infliximab: case report.

  2011cites this paper
• Permanent renal loss following tumor necrosis factor α antagonists for arthritis

  2010cites this paper
• How to manage the infectious risk under anti-TNF in inflammatory bowel disease.

  2010cites this paper
• Drug-induced and Iatrogenic Respiratory Disease

  2010cites this paper
• An update on Cryptococcus among HIV-infected patients

  2010cites this paper
• Epidemiology of Invasive Mycoses in North America

  2010cites this paper
• Antifungal therapy in invasive fungal infections.

  2010cites this paper
• Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

  2010cites this paper
• Overlapping presentation of fungal tubulointerstitial nephritis in an immunosuppressed pediatric patient

  2009cites this paper
• Disseminated Cryptococcal Infection and Anti-Tumor Necrosis Factor-α Treatment for Refractory Sarcoidosis: An Expected Association?

  2009cites this paper
• European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

  2009cites this paper
• [Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNFalpha) therapy].

  2009cites this paper
• Incidence and nature of infectious disease in patients treated with anti-TNF agents.

  2009cites this paper
• Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung.

  2009cites this paper
• Continuing Education Course – Mycoses

  2009cites this paper
• Pulmonary complications of tumor necrosis factor-targeted therapy.

  2009cites this paper
• Chapter 3--pulmonary cryptococcosis.

  2009cites this paper
• Accumulation of CD11b+ Lung Dendritic Cells in Response to Fungal Infection Results from the CCR2-Mediated Recruitment and Differentiation of Ly-6Chigh Monocytes12

  2009cites this paper
• Chest pain as presenting symptom of Staphyloccocus aureus epidural abscess associated with anti-tumor necrosis factor and methotrexate therapy.

  2009cites this paper
• Coinfección oportunista durante el tratamiento con infliximab (antifactor de necrosis tumoral alfa) en un paciente con enfermedad de Crohn

  2009cites this paper
• Invasive fungal infections in the era of biologics.

  2009cites this paper
• Fungal infections complicating tumor necrosis factor alpha blockade therapy.

  2008cites this paper
• Pulmonary Cryptococcosis

  2008cites this paper
• Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription

  2008cites this paper
• Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab.

  2008cites this paper
• Disseminated Cryptococcus neoformans after treatment with infliximab for rheumatoid arthritis.

  2008cites this paper
• A Case of Cryptococcal Pneumonia in a Rheumatoid Arthritis Patient after Tumor Necrosis Factor-alpha Antagonist Therapy

  2007cites this paper
• Invasive Cryptococcosis and Adalimumab Treatment

  2007cites this paper
• Determining Risk Factors for Infection with Influenza A (H5N1)

  2007cites this paper
• Cryptococcal meningitis in a patient treated with infliximab.

  2007cites this paper
• Mammalian model hosts of cryptococcal infection.

  2007cites this paper
• Impact of biologic agents on infectious diseases.

  2006cites this paper
• [Biologic therapy and infections].

  2006cites this paper
• Risiko von Infektionen unter einer Behandlung mit Tumornekrosefaktor-α-Inhibitoren

  2006cites this paper
• [Risk of infection during treatment with tumor necrosis factor-alpha inhibitors].

  2006cites this paper
• Problems encountered during anti-tumour necrosis factor therapy.

  2006cites this paper
• [Cerebral cryptococcosis associated with etanercept].

  2006cites this paper
• Cryptococcosis.

  2006cites this paper
• The Physical Properties of the Capsular Polysaccharides from Cryptococcus neoformans Suggest Features for Capsule Construction*

  2006cites this paper
• Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy.

  2006cites this paper
• Infectious complications of tumor necrosis factor-alpha antagonists.

  2005cites this paper
• Guidelines Update on the British Society for Rheumatology guidelines for prescribing TNF a blockers in adults with rheumatoid arthritis ( update of previous guidelines of April 2001 )

  2005cites this paper
• Cryptococcal fungemia in a neutropenic patient with AIDS while receiving caspofungin.

  2005cites this paper
• Infections associated with tumor necrosis factor-alpha antagonists.

  2005cites this paper
• Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease.

  2005cites this paper
• Immunosuppression related to collagen-vascular disease or its treatment.

  2005cites this paper
• Infectious complications of tumor necrosis factor‐α antagonists

  2005cites this paper
• Infections Associated With Tumor Necrosis Factor-α Antagonists

  2005cites this paper
• Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).

  2005cites this paper
• Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).

  2005cites this paper
• Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab)

  2005cites this paper
• MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans

  2005cites this paper
• Tumor necrosis factor antagonists and infections: the small print on the price tag.

  2005cites this paper
• Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.

  2005cites this paper
• Infectious complications of treatment with biologic agents

  2004cites this paper
• Cavitating pneumonia after treatment with infliximab and prednisone

  2004cites this paper